Skip to main content
. 2018 Aug 6;9:1761. doi: 10.3389/fimmu.2018.01761

Figure 1.

Figure 1

Circulating Tfh and Tfr cells in an individual with CD40 deficiency compared to patients with CD40L and AICDA mutations. (A) Percentage of Tfh (gated on singlets → lymphocytes → CD3+CD19−CD14−CD8− → CD4+CD3+) in healthy pediatric (3–15 years, n = 7, HC_ped) and healthy adult (19–31 years, n = 9; HC_adult) healthy controls (HCs). (B) Representative flow cytometry plots for Tfh (CXCR5+FOXP3−), Tfr (CXCR5+FOXP3+), and T regulatory (Treg) (CXCR5−FOXP3+) cells, gated on singlets → lymphocytes → CD3+CD19−CD14−CD8− → CD4+CD3+ in hyper-IgM (HIGM) patients and age-matched HCs. (C–E) Percentage of Tfh (C), Tfr (D), and Treg (E) cells in pediatric [CD40 ligand (CD40L), n = 5; activation-induced cytidine deaminase (AID), n = 2; CD40, n = 1] and adult (CD40L, n = 2; AID, n = 1) HIGM patients, compared with age-matched HCs [same as in panel (A)]. (F) Tfh:Tfr ratio cells in pediatric and adult HIGM patients (AID, CD40L, and CD40 deficiency, as indicated) compared with age-matched HCs. Bars: mean ± SEM. *p < 0.05 (Mann–Whitney test). Each dot represents one patient. Black & white squares represent longitudinal measurements of the same CD40L-deficient patient, collected at 14 and 19 years of age.